The LiBBY trial found that a purified THC and CBD oil reduced agitation in hospice-eligible people with late-stage dementia. For people with mild cognitive impairment, which means early memory slips with daily function largely intact, researchers still need to learn if any dose is safe or helpful. The Phase 2 trial randomized 120 people with advanced Alzheimer's or other dementia and significant agitation to active oil or placebo. The LiBBY Study official site reports results were first presented at AAIC 2026 in London on July 14 the LiBBY Study results announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did LiBBY test?
- How much did agitation improve?
- What did safety show in very late-stage illness?
- Why do results not apply to mild cognitive impairment?
- What must MCI research answer next?
What did LiBBY test?
Active treatment was 2 mg THC plus 100 mg CBD twice daily for 12 weeks after a half-dose first week. NeurologyLive reports it was a purified oral oil given at home across 10 U.S.
centers versus matching placebo the NeurologyLive report. Participants were hospice-eligible and very frail, with a mean age of 80. That frailty shapes both the possible benefit and the risks.
How much did agitation improve?
Agitation was measured with CMAI scores, a caregiver rating of restless and aggressive behaviors. Psychiatric Times reports scores fell 10.61 points on THC and CBD versus 4.35 on placebo at week 2, a 6.27-point difference the Psychiatric Times report.
Benefit persisted to week 12 with an 8.23-point mean advantage. Clinicians rated global improvement in 87.2% on treatment versus 23.6% on placebo.
What did safety show in very late-stage illness?
Overall adverse events were similar, 46.7% on treatment versus 42.4% on placebo. Serious events were higher with THC and CBD, 23.3% versus 11.9%.
Serious infections and deaths were also higher on treatment. Investigators judged these events unrelated and expected in end-of-life patients.
Why do results not apply to mild cognitive impairment?
The trial enrolled only hospice-eligible late-stage patients. Georgetown School of Medicine notes the narrow population does not establish efficacy, dosing, or cognitive safety for mild cognitive impairment the Georgetown report.
The tested product was also specific. Results apply only to the investigational T2:C100 formulation and delivery system, not to dispensary or over-the-counter cannabis.
What must MCI research answer next?
For early memory changes, the questions are different from comfort care at end of life. Readers with MCI often want to preserve thinking, driving, work, and independence. People with memory concerns should not substitute public cannabis products for the investigational oil.
- Does any THC and CBD dose reduce distress without harming memory or attention?
- What dose and ratio, if any, fits older adults with other medicines?
- How do effects change over months, not just 12 weeks?
- Who faces higher fall, confusion, or heart risks?
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Researchers Still Need to Learn for People With Mild Cognitive Impairment
- AAIC 2026 PROTECT-Cog Lifestyle and GLP-1 Trial: What Researchers Still Need to Learn for People With Mild Cognitive Impairment
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
